Table 2.
Patient-assessed dyspnoea treatment response by severity of dyspnoea at baseline
Baseline dyspnoea status | TLV/PLC, n | % improved |
Treatment group difference (%) | P-value | |
---|---|---|---|---|---|
Tolvaptan | Placebo | ||||
Seldoma | 153/164 | 71.89 | 70.12 | 1.77 | 0.6934 |
Frequent | 1247/1244 | 73.62 | 69.05 | 4.57 | 0.0013 |
Continuous | 588/585 | 75.95 | 65.65 | 10.30 | 0.0021 |
Note: baseline dyspnoea status determined by investigator. Per cent improved based on patient self-assessment.
aNot included in overall analyses.